Now showing items 1-20 of 22
Guerrero Barrado, Pedro Enrique (Date of defense: 2020-07-29)
Pancreatic Ductal Adenocarcinoma (PDA), the most common pancreatic cancer, remains one of the most lethal tumor types, with extremely low survival rates due to late diagnosis and resistance to standard therapies. Expression ...
Gratacós Mulleras, Anna (Date of defense: 2024-07-05)
The prostate-specific antigen (PSA) is the reference biomarker for prostate cancer (PCa) diagnosis. This biomarker is increased in PCa, but also in benign prostate hyperplasia (BPH) causing a high number of unnecessary ...
Carrion-Salip, Dolors (Date of defense: 2014-09-17)
Most current chemotherapeutic agents are of limited use due to their side effects and the resistance to treatment that tumour cells develop. In this thesis, we have contributed to the knowledge of these limitations through ...
Panosa Roqueta, Clara (Date of defense: 2015-12-14)
The members of the epidermal growth factor (EGF) / ErbB family are prime targets for cancer therapy. However, the therapeutic efficiency of the existing anti-ErbB agents is limited. Thus, identifying new molecules that ...
Cufí González, Sílvia (Date of defense: 2015-05-22)
Aquest és el primer informe que demostra que l'autofàgia està mecànicament vinculat al manteniment de les cèl•lules tumorals que expressen alts nivells de CD44 i baixos nivells de CD24, que són típics de les cèl•lules mare ...
Díaz Santa, Johana Alejandra (Date of defense: 2022-12-16)
Acute myeloid leukemia (AML) is adults' most common acute leukemia. Prognostic factors influencing treatment response and patient survival are diverse, the most relevant being those associated with specific cytogenetic and ...
Farrés Coll, Ramon (Date of defense: 2023-03-10)
Introduction: Anastomotic leak (AL) is the most feared complication in the postoperative period for patients with rectal cancer. Objectives: To determine the real rate of AL in patients operated on for rectal cancer. ...
Ferrer Soler, Laura (Date of defense: 2007-03-30)
L'inhibidor de carboxipeptidasa de patata (PCI) és un antagonista de l'EGF. Un dels problemes del PCI, però, és la baixa afinitat per l'EGFR en comparació amb el lligand natural. En aquest treball s'han dissenyat nous ...
Santos Carvajal, Nazly (Date of defense: 2022-11-25)
Study of the impact of UGT2B17 and PD-1 on allogeneic transplantation of hematopoietic progenitors (allo-TPH) from HLA-identical related donor. everal genetic factors can favor the development of graft-versus-host disease ...
Pigem Rodeja, Anna (Date of defense: 2023-03-03)
INTRODUCTION: Anastomotic leak (AL) is the most dreadful and life-threatening complication in colon cancer (CC) surgery. It is associated to an increase of morbimortality, longer hospital stay, increased healthcare costs ...
Sarrats Carbó, Ariadna (Date of defense: 2011-02-10)
Els pacients amb càncer presenten una taxa de supervivència superior si es diagnostiquen a estadis inicials, per la qual cosa és indispensable disposar de marcadors tumorals adequats. Glicoformes de proteïnes específiques ...
Blanco Aparicio, Carmen (Date of defense: 1998-07-17)
In this work we report that potato carboxypeptidase inhibitor suppresses the growth of several human and mouse pancreatic adenocarcinoma cell lines. The inhibitor also reduces the growth of solid tumors obtained by ...
Miró Domènech, Laura (Date of defense: 2023-01-13)
Pancreatic ductal adenocarcinoma (PDA) presents a dismal prognosis mainly due to its delayed diagnosis, its aggressiveness, and resistance to existing therapies. Aberrant glycosylation and, in particular, the overexpression ...
Ferri Iglesias, María José (Date of defense: 2012-09-27)
Serum levels of several molecules associated to pancreatic adenocarcinoma (PDAC) pathophysiology are evaluated in this work, in order to determine their diagnostic value, distinguishing between PDAC patients and healthy ...
Duran Sidera, Adrià (Date of defense: 2023-11-14)
Pancreatic cancer (PaC) is the deadliest of all tumours, with a 5-year survival below 12% and a mortality/incidence ratio of 94.5%. One of the main reasons behind this dismal prognosis is the diagnosis of the disease at ...
Chico Julià, Berta (Date of defense: 2009-02-19)
La DM 2 és una malaltia multifactorial i multigènica. Aquest fet condueix a l'estudi de molts gens i proteïnes susceptibles d'estar implicades amb la DM 2. Algunes d'aquestes proteïnes i gens estan associats a un estat ...
Oliveras Ferrarós, Cristina (Date of defense: 2013-06-21)
The aim of this doctoral thesis was to unravel mechanisms underlying primary resistance to trastuzumab regarding a putative new breast cancer subtype with mixed basal & ErbB2+ molecular features. Using the JIMT-1 breast ...
Balmaña Esteban, Meritxell (Date of defense: 2016-07-07)
Cancer is one of the leading causes of death worldwide. Pancreatic ductal adenocarcinoma (PDAC) is characterized by high intrinsic aggressiveness and late diagnosis, causing poor prognosis and resulting in the lowest ...
Gonzalez Montes, Yolanda (Date of defense: 2024-04-12)
Multiple myeloma (MM) remains an incurable disease despite the incorporation of new therapies. The natural history of disease is of the relapse following treatments due to the re-emergence of the tumour from residual disease ...
Pérez Garay, Marta (Date of defense: 2011-02-07)
Este trabajo demuestra que los genes que codifican para los enzimas beta-galactosido alfa-2,3-sialiltransferasa 3 (ST3Gal III), y en menor medida beta-galactosido alfa-2,3-sialiltransferasa 4 (ST3Gal IV), están directamente ...